Tenderwize
Back to tender search

Open-House non-exclusive rebate agreement for BeclometasonFormoterolGlycopyrronium

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jan 31, 2027 · 115 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff BeclometasonFormoterolGlycopyrronium (ATC-Code nach WHO: R03AL09)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

Structured data says electronic submission is not allowed, while the notice text says communication and transmission oc...

Important participation documents are referenced but not fully provided in the extracted text, especially 'Anschreiben'...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jan 31, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Non-exclusive supply/rebate agreement for pharmaceutical products containing BeclometasonFormoterolGlycopyrronium (ATC R03AL09).
  • Open-House model: contract conclusion is open to all interested companies during the participation period if they meet and accept the conditions.
Show full summary

This is an Open-House pharmaceutical supply arrangement for the active substance BeclometasonFormoterolGlycopyrronium (ATC R03AL09) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet and accept the participation conditions. No contract value, minimum purchase volume, or guaranteed demand is stated. Participation documents are available via DTVP, but the extracted procurement documents were not provided for analysis, so document-based requirements may be incomplete.

Risks

Structured data says electronic submission is not allowed, while the notice text says communication and transmission oc...

Important participation documents are referenced but not fully provided in the extracted text, especially 'Anschreiben'...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must submit the self-declaration on the absence of exclusion grounds under §§ 123, 124 GWB.

Administrative

  • The bidder must submit the self-declaration regarding EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576).

Award Criteria

Lot 1

No lot-specific award criteria stated; Open-House participation is based on meeting and accepting the stated conditions.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Open-House non-exclusive rebate agreement for BeclometasonFormoterolGlycopyrronium

Supply lot for a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V for the active substance BeclometasonFormoterolGlycopyrronium (ATC R03AL09). The arrangement is an Open-House model, so any interested pharmaceutical company meeting the conditions may participate. Place of performance is Dresden, Germany. Lot information comes from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jan 2025 - Jan 2027

Category

Pharmaceutical products

Award Criteria

No lot-specific award criteria stated; Open-House participation is based on meeting and accepting the stated conditions.

Deadline

Deadline Jan 31, 2027

Procurement Details

Publication date
03 Dec 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
738758-2024

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30